Federal Circuit / U.S. Court of Spec. Jurisdiction

Federal Circuit / U.S. Court of Spec. Jurisdiction
(incl: International Trade (Customs), Federal Claims, Armed Forces, Federal Adm. Agencies & Boards, Immigration, Tax, Gov. Personnel Appeals, Patent , Trademark, Veterans Appeals, etc.)

Custom text Title Organization
Oct
11
2016
 Federal Circuit Affirms 101 Ineligibility of a Patent Claiming Detection of Unauthorized Access to Medical Information Schwegman, Lundberg & Woessner, P.A.
Feb
23
2017
 Federal Circuit Affirms a District Court’s Claim Construction, Dispositive of the Determination of Non-Infringement Hunton Andrews Kurth
Nov
16
2017
 Federal Circuit Affirms Delaware Alice Decision Mintz
Mar
6
2023
 Federal Circuit Affirms Delisting of REMS System Patent from FDA Orange Book Mintz
Nov
12
2021
 Federal Circuit Affirms Dismissal of Hatch-Waxman Defendants for Lack of Venue and Failure to State a Claim Mintz
Jul
1
2015
 Federal Circuit Affirms Dismissal on Grounds of Patent Ineligibility Mintz
Oct
2
2014
 Federal Circuit Affirms Dismissal Where Co-Owner of Patent Refuses to Join Suit Mintz
May
24
2016
 Federal Circuit Affirms Finacea Gel Infringement Under Doctrine of Equivalents Foley & Lardner LLP
Nov
24
2012
 Federal Circuit Affirms Finding of Obviousness in DNA Patent Application McDermott Will & Emery
Feb
23
2017
 Federal Circuit Affirms Induced Infringement and No Validity of the Asserted Patent, the Inducement Being Determined in Accordance with an Interim En Banc Decision by the Court Hunton Andrews Kurth
Oct
10
2013
 Federal Circuit Affirms Inequitable Conduct Determination Under Therasense “But For” Exception and Reaffirms Significance of Rohm & Haas Sheppard, Mullin, Richter & Hampton LLP
Mar
31
2013
 Federal Circuit Affirms Injunction Against Impax Labs and Bars Generic Introduction McDermott Will & Emery
Dec
2
2021
 Federal Circuit Affirms Invalidity of Method of Treatment Patent for Lack of Written Description in Hatch-Waxman Case Polsinelli PC
Oct
11
2011
 Federal Circuit Affirms Non-Obviousness Summary Judgment for Novel Formulation of Prior Art Active Drug Compound McDermott Will & Emery
Apr
25
2024
 Federal Circuit Affirms Obviousness of Rifaximin Polymorph Patents and Denial of Motion to Modify Judgment After Post-Trial Patented Indication Carve Out Mintz
May
1
2012
 Federal Circuit Affirms Pre-Therasense Finding of Inequitable Conduct Hunton Andrews Kurth
Feb
16
2016
 Federal Circuit Affirms Pro-Patent Owner Limits on Patent Exhaustion Neal, Gerber & Eisenberg LLP
Feb
5
2019
 Federal Circuit Affirms PTAB Lead Compound Analysis Upholding Vimpat Lacosamide Patent Foley & Lardner LLP
Jul
21
2018
 Federal Circuit Affirms PTAB Ruling That Tribal Immunity Does Not Apply To IPRs Foley & Lardner LLP
Dec
17
2015
 Federal Circuit Affirms PTAB's IPR Decision Invalidating A Pharmaceutical Patent Foley & Lardner LLP
May
19
2021
 Federal Circuit Affirms PTAB’s Claim Construction and Obviousness Analysis for VoIP Patent Finnegan
Feb
25
2015
 Federal Circuit Affirms PTAB’s Lack of Patentability Ruling in First-Ever AIA Review: In re Cuozzo Speed Techs., LLC McDermott Will & Emery
Mar
18
2021
 Federal Circuit Affirms PTAB’s Rejection of Patent Application as Abstract Finnegan
Dec
21
2023
 Federal Circuit Affirms PTAB’s Ruling of Obviousness for the Colorization of Fabrics Sheppard, Mullin, Richter & Hampton LLP
Dec
15
2023
 Federal Circuit Affirms PTAB’s Ruling of Swearing Behind a Prior Art Reference Sheppard, Mullin, Richter & Hampton LLP
Jun
20
2016
 Federal Circuit Affirms Refusal to Register “Churrascos” Based on Genericness, Despite Prior Federal Registration of the Mark Sheppard, Mullin, Richter & Hampton LLP
Dec
20
2019
 Federal Circuit affirms Safe Harbor ruling and $70 million award in Amgen Inc. v. Hospira, Inc. Mintz
Jan
18
2024
 Federal Circuit Affirms Skinny Label Carve Outs Sheppard, Mullin, Richter & Hampton LLP
Jun
14
2012
 Federal Circuit Affirms Structural Obviousness Analysis McDermott Will & Emery
May
30
2019
 Federal Circuit Affirms that Likelihood of Confusion – not “Use in Commerce” – is the Hallmark of Trademark Infringement Squire Patton Boggs (US) LLP
Apr
21
2017
 Federal Circuit Affirms the PTAB’s Decision Finding the Patent Claims Unpatentable as Obvious Where the Patent Owner Did Not Demonstrate that the Board Violated the Administrative Procedure Act Requirements of Notice and an Opportunity to Respond Hunton Andrews Kurth
Aug
23
2016
 Federal Circuit Affirms Tygacil Formulation Patent Foley & Lardner LLP
Feb
14
2017
 Federal Circuit Again Reverses PTAB Obviousness Determination Foley & Lardner LLP
Aug
13
2019
 Federal Circuit Agrees Genotyping Method Is Not Eligible For Patenting Foley & Lardner LLP
Feb
10
2021
 Federal Circuit Agrees to Reconsider Ruling in GSK v. Teva Drug Patent Case Sheppard, Mullin, Richter & Hampton LLP
Subscribe to Federal Circuit / U.S. Court of Spec. Jurisdiction
 

NLR Logo

We collaborate with the world's leading lawyers to deliver news tailored for you. Sign Up to receive our free e-Newsbulletins

 

Sign Up for e-NewsBulletins